Infliximab, Serum
Test Mnemonic
INFLIX
CPT Codes
- 80230 - QTY (1)
- 80307 - QTY (1)
Performing Laboratory
Cleveland Clinic Laboratories
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | No additive (Red) | Refrigerated |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |
Days Performed
Mon, Thu
Turnaround Time
1 - 4 days
Methodology
| Name | Description |
|---|---|
| Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |
Reference Range
| Infliximab Total Anti-Drug Antibody Level | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | <10 | AU/mL | |||
| Infliximab Total Drug Level | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | >=5 | ug/mL |
Special Info
Patients taking a biotin dose greater than 5 mg/day should refrain from taking biotin for at least 24 hours. Clinicians should consider biotin interference as a source of error, when clinically suspicious of the laboratory result. Performing Labs: Immunopathology (x49026) and Special Chemistry (x42525).
Clinical Info
Trough total (free and bound) infliximab level and total (free and bound) anti-drug antibody levels for patients undergoing therapy with infliximab, -abda, -dyyb, and -axxq. Draw just prior to scheduled dose. In adults with active IBD treated with anti-TNF agents, the AGA suggests reactive therapeutic drug monitoring to guide treatment changes. Reference ranges and high/low indicator flags are provided as general guidelines only. The treating physician must determine appropriate target levels/dosing based on the specific clinical situation.
Clinical Limitation
Infliximab drug levels greater than 25 ug/mL may result in falsely-decreased infliximab anti-drug antibody levels.